{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:44:59Z","timestamp":1787003099711,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Canadian Consortium on Neurodegeneration in Aging"},{"name":"The GBA1-Canada initiative"},{"name":"The Hilary and Galen Weston Foundation and The Van Berkom family"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"DOI":"10.1038\/s41531-025-01197-4","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T12:06:45Z","timestamp":1765282005000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["No evidence for genetic role of the tumor necrosis factor pathway in Parkinson\u2019s disease"],"prefix":"10.1038","volume":"11","author":[{"given":"Morvarid","family":"Ghamgosar Shahkhali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma N.","family":"Somerville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair J.","family":"Noyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziv","family":"Gan-Or","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Senkevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"1197_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe, W. et al. Parkinson disease. Nat. Rev. Dis. Prim. 3, 17013 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1197_CR2","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/4784268","volume":"2018","author":"G Gelders","year":"2018","unstructured":"Gelders, G., Baekelandt, V. & Van der Perren, A. Linking Neuroinflammation and Neurodegeneration in Parkinson\u2019s Disease. J. Immunol. Res 2018, 4784268 (2018).","journal-title":"J. Immunol. Res"},{"key":"1197_CR3","doi-asserted-by":"publisher","first-page":"S210","DOI":"10.1016\/S1353-8020(11)70065-7","volume":"18","author":"EC Hirsch","year":"2012","unstructured":"Hirsch, E. C., Vyas, S. & Hunot, S. Neuroinflammation in Parkinson\u2019s disease. Parkinsonism Relat. Disord. 18, S210\u2013S212 (2012).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1197_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2022.105376","volume":"158","author":"R Amin","year":"2022","unstructured":"Amin, R. et al. The role of Tumour Necrosis Factor in neuroinflammation associated with Parkinson\u2019s disease and targeted therapies. Neurochem Int 158, 105376 (2022).","journal-title":"Neurochem Int"},{"key":"1197_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40035-015-0042-0","volume":"4","author":"Q Wang","year":"2015","unstructured":"Wang, Q., Liu, Y. & Zhou, J. Neuroinflammation in Parkinson\u2019s disease and its potential as therapeutic target. Transl. Neurodegener. 4, 19, (2015).","journal-title":"Transl. Neurodegener."},{"key":"1197_CR6","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1016\/j.neuropharm.2012.01.028","volume":"62","author":"LM Collins","year":"2012","unstructured":"Collins, L. M., Toulouse, A., Connor, T. J. & Nolan, Y. M. Contributions of central and systemic inflammation to the pathophysiology of Parkinson\u2019s disease. Neuropharmacology 62, 2154\u20132168 (2012).","journal-title":"Neuropharmacology"},{"key":"1197_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.636139","volume":"12","author":"AF Magnusen","year":"2021","unstructured":"Magnusen, A. F., Hatton, S. L., Rani, R. & Pandey, M. K. Genetic Defects and Pro-inflammatory Cytokines in Parkinson\u2019s Disease. Front Neurol. 12, 636139 (2021).","journal-title":"Front Neurol."},{"key":"1197_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.neulet.2017.08.049","volume":"658","author":"JD Lindenau","year":"2017","unstructured":"Lindenau, J. D., Altmann, V., Schumacher-Schuh, A. F., Rieder, C. R. & Hutz, M. H. Tumor necrosis factor alpha polymorphisms are associated with Parkinson\u2019s disease age at onset. Neurosci. Lett. 658, 133\u2013136 (2017).","journal-title":"Neurosci. Lett."},{"key":"1197_CR9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1017\/S0317167100012695","volume":"39","author":"K Chu","year":"2012","unstructured":"Chu, K., Zhou, X. & Luo, B. Y. Cytokine gene polymorphisms and Parkinson\u2019s disease: a meta-analysis. Can. J. Neurol. Sci. 39, 58\u201364 (2012).","journal-title":"Can. J. Neurol. Sci."},{"key":"1197_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jns.2017.12.011","volume":"385","author":"C Agliardi","year":"2018","unstructured":"Agliardi, C. et al. TNF-alpha -308 G\/A and -238 G\/A promoter polymorphisms and sporadic Parkinson\u2019s disease in an Italian cohort. J. Neurol. Sci. 385, 45\u201348 (2018).","journal-title":"J. Neurol. Sci."},{"key":"1197_CR11","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","volume":"18","author":"MA Nalls","year":"2019","unstructured":"Nalls, M. A. et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson\u2019s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 18, 1091\u20131102 (2019).","journal-title":"Lancet Neurol."},{"key":"1197_CR12","doi-asserted-by":"publisher","unstructured":"Program, T. G. P. s. G. & Leonard, H. L. Novel Parkinson\u2019s Disease Genetic Risk Factors Within and Across European Populations. medRxiv, 2025.2003.2014.24319455. https:\/\/doi.org\/10.1101\/2025.03.14.24319455 (2025).","DOI":"10.1101\/2025.03.14.24319455"},{"key":"1197_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34732-5","volume":"13","author":"L Krohn","year":"2022","unstructured":"Krohn, L. et al. Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effects. Nat. Commun. 13, 7496 (2022).","journal-title":"Nat. Commun."},{"key":"1197_CR14","doi-asserted-by":"publisher","first-page":"e1672","DOI":"10.1212\/WNL.0000000000011630","volume":"96","author":"X Kang","year":"2021","unstructured":"Kang, X. et al. Tumor Necrosis Factor Inhibition and Parkinson Disease: A Mendelian Randomization Study. Neurology 96, e1672\u2013e1679 (2021).","journal-title":"Neurology"},{"key":"1197_CR15","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1093\/brain\/awac193","volume":"145","author":"D Bottigliengo","year":"2022","unstructured":"Bottigliengo, D. et al. A Mendelian randomization study investigating the causal role of inflammation on Parkinson\u2019s disease. Brain 145, 3444\u20133453 (2022).","journal-title":"Brain"},{"key":"1197_CR16","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3233\/JPD-240353","volume":"14","author":"B Patel","year":"2024","unstructured":"Patel, B., Greenland, J. C. & Williams-Gray, C. H. Clinical Trial Highlights: Anti-Inflammatory and Immunomodulatory Agents. J. Parkinsons Dis. 14, 1283\u20131300 (2024).","journal-title":"J. Parkinsons Dis."},{"key":"1197_CR17","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.neulet.2008.06.040","volume":"441","author":"B Brodacki","year":"2008","unstructured":"Brodacki, B. et al. Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci. Lett. 441, 158\u2013162 (2008).","journal-title":"Neurosci. Lett."},{"key":"1197_CR18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1600-0404.1999.tb00721.x","volume":"100","author":"RJ Dobbs","year":"1999","unstructured":"Dobbs, R. J. et al. Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol. Scand. 100, 34\u201341 (1999).","journal-title":"Acta Neurol. Scand."},{"key":"1197_CR19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.clineuro.2018.01.022","volume":"166","author":"E Kouchaki","year":"2018","unstructured":"Kouchaki, E. et al. Increased serum levels of TNF-alpha and decreased serum levels of IL-27 in patients with Parkinson disease and their correlation with disease severity. Clin. Neurol. Neurosurg. 166, 76\u201379 (2018).","journal-title":"Clin. Neurol. Neurosurg."},{"key":"1197_CR20","doi-asserted-by":"publisher","unstructured":"Huxford, B. et al. Plasma Neurofilament Light Chain and TNF-alpha Correlate with Motor Features in Isolated REM Sleep Behavior Disorder. Mov.Disord. Clin. Pract. https:\/\/doi.org\/10.1002\/mdc3.70210 (2025).","DOI":"10.1002\/mdc3.70210"},{"key":"1197_CR21","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jneuroim.2009.08.001","volume":"216","author":"P Scalzo","year":"2009","unstructured":"Scalzo, P., Kummer, A., Cardoso, F. & Teixeira, A. L. Increased serum levels of soluble tumor necrosis factor-alpha receptor-1 in patients with Parkinson\u2019s disease. J. Neuroimmunol. 216, 122\u2013125 (2009).","journal-title":"J. Neuroimmunol."},{"key":"1197_CR22","doi-asserted-by":"publisher","first-page":"e47387","DOI":"10.1371\/journal.pone.0047387","volume":"7","author":"D Lindqvist","year":"2012","unstructured":"Lindqvist, D. et al. Non-motor symptoms in patients with Parkinson\u2019s disease - correlations with inflammatory cytokines in serum. PLoS One 7, e47387 (2012).","journal-title":"PLoS One"},{"key":"1197_CR23","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1001\/jamaneurol.2018.0605","volume":"75","author":"I Peter","year":"2018","unstructured":"Peter, I. et al. Anti-Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease. JAMA Neurol. 75, 939\u2013946 (2018).","journal-title":"JAMA Neurol."},{"key":"1197_CR24","doi-asserted-by":"publisher","first-page":"9365","DOI":"10.1523\/JNEUROSCI.1504-06.2006","volume":"26","author":"MK McCoy","year":"2006","unstructured":"McCoy, M. K. et al. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson\u2019s disease. J. Neurosci. 26, 9365\u20139375 (2006).","journal-title":"J. Neurosci."},{"key":"1197_CR25","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1038\/mt.2008.146","volume":"16","author":"MK McCoy","year":"2008","unstructured":"McCoy, M. K. et al. Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats. Mol. Ther. 16, 1572\u20131579 (2008).","journal-title":"Mol. Ther."},{"key":"1197_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2025.106841","volume":"207","author":"F Fredlund","year":"2025","unstructured":"Fredlund, F. et al. Lack of neuroprotection after systemic administration of the soluble TNF inhibitor XPro1595 in an rAAV6-alpha-Syn + PFFs-induced rat model for Parkinson\u2019s disease. Neurobiol. Dis. 207, 106841 (2025).","journal-title":"Neurobiol. Dis."},{"key":"1197_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2025.106803","volume":"206","author":"JR Christiansen","year":"2025","unstructured":"Christiansen, J. R. et al. Peripherally administered TNF inhibitor is not protective against alpha-synuclein-induced dopaminergic neuronal death in rats. Neurobiol. Dis. 206, 106803 (2025).","journal-title":"Neurobiol. Dis."},{"key":"1197_CR28","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/bs.mcb.2025.02.006","volume":"197","author":"JA Morales-Garcia","year":"2025","unstructured":"Morales-Garcia, J. A. Modeling neurodegeneration and neuroinflammation in Parkinson\u2019s Disease: Animal-based strategies. Methods Cell Biol. 197, 81\u2013114 (2025).","journal-title":"Methods Cell Biol."},{"key":"1197_CR29","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1038\/s41588-024-01896-3","volume":"56","author":"QS Wang","year":"2024","unstructured":"Wang, Q. S. et al. Statistically and functionally fine-mapped blood eQTLs and pQTLs from 1,405 humans reveal distinct regulation patterns and disease relevance. Nat. Genet 56, 2054\u20132067 (2024).","journal-title":"Nat. Genet"},{"key":"1197_CR30","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41586-024-07316-0","volume":"629","author":"EV Minikel","year":"2024","unstructured":"Minikel, E. V., Painter, J. L., Dong, C. C. & Nelson, M. R. Refining the impact of genetic evidence on clinical success. Nature 629, 624\u2013629 (2024).","journal-title":"Nature"},{"key":"1197_CR31","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ng.3538","volume":"48","author":"Z Zhu","year":"2016","unstructured":"Zhu, Z. et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat. Genet 48, 481\u2013487 (2016).","journal-title":"Nat. Genet"},{"key":"1197_CR32","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1038\/s41588-022-01154-4","volume":"54","author":"T Qi","year":"2022","unstructured":"Qi, T. et al. Genetic control of RNA splicing and its distinct role in complex trait variation. Nat. Genet 54, 1355\u20131363 (2022).","journal-title":"Nat. Genet"},{"key":"1197_CR33","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.aaz1776","volume":"369","author":"TG Consortium","year":"2020","unstructured":"Consortium, T. G. et al. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science 369, 1318\u20131330 (2020).","journal-title":"Science"},{"key":"1197_CR34","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1002\/mds.27845","volume":"34","author":"H Iwaki","year":"2019","unstructured":"Iwaki, H. et al. Genomewide association study of Parkinson\u2019s disease clinical biomarkers in 12 longitudinal patients\u2019 cohorts. Mov. Disord. 34, 1839\u20131850 (2019).","journal-title":"Mov. Disord."},{"key":"1197_CR35","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41531-024-00729-8","volume":"10","author":"MMX Tan","year":"2024","unstructured":"Tan, M. M. X. et al. Genome-wide determinants of mortality and motor progression in Parkinson\u2019s disease. NPJ Parkinsons Dis. 10, 113 (2024).","journal-title":"NPJ Parkinsons Dis."},{"key":"1197_CR36","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","volume":"562","author":"C Bycroft","year":"2018","unstructured":"Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 562, 203\u2013209 (2018).","journal-title":"Nature"},{"key":"1197_CR37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41588-023-01584-8","volume":"56","author":"JJ Kim","year":"2024","unstructured":"Kim, J. J. et al. Multi-ancestry genome-wide association meta-analysis of Parkinson\u2019s disease. Nat. Genet 56, 27\u201336 (2024).","journal-title":"Nat. Genet"},{"key":"1197_CR38","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J. R. Stat. Soc.: Ser. B (Methodol.) 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc.: Ser. B (Methodol.)"},{"key":"1197_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, 122 (2016).","journal-title":"Genome Biol."},{"key":"1197_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/biostatistics\/kxv033","volume":"17","author":"S Lee","year":"2016","unstructured":"Lee, S., Fuchsberger, C., Kim, S. & Scott, L. An efficient resampling method for calibrating single and gene-based rare variant association analysis in case-control studies. Biostatistics 17, 1\u201315 (2016).","journal-title":"Biostatistics"},{"key":"1197_CR41","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ajhg.2012.06.007","volume":"91","author":"S Lee","year":"2012","unstructured":"Lee, S. et al. Optimal unified approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies. Am. J. Hum. Genet 91, 224\u2013237 (2012).","journal-title":"Am. J. Hum. Genet"},{"key":"1197_CR42","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ajhg.2013.05.010","volume":"93","author":"S Lee","year":"2013","unstructured":"Lee, S., Teslovich, T. M., Boehnke, M. & Lin, X. General framework for meta-analysis of rare variants in sequencing association studies. Am. J. Hum. Genet 93, 42\u201353 (2013).","journal-title":"Am. J. Hum. Genet"},{"key":"1197_CR43","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1093\/bioinformatics\/btab186","volume":"37","author":"AP Boughton","year":"2021","unstructured":"Boughton, A. P. et al. LocusZoom.js: interactive and embeddable visualization of genetic association study results. Bioinformatics 37, 3017\u20133018 (2021).","journal-title":"Bioinformatics"},{"key":"1197_CR44","doi-asserted-by":"publisher","first-page":"e1010624","DOI":"10.1371\/journal.pgen.1010624","volume":"19","author":"SW Choi","year":"2023","unstructured":"Choi, S. W. et al. PRSet: Pathway-based polygenic risk score analyses and software. PLoS Genet 19 e1010624 (2023).","journal-title":"PLoS Genet"}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01197-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01197-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01197-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:04:09Z","timestamp":1784117049000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01197-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1197"],"URL":"https:\/\/doi.org\/10.1038\/s41531-025-01197-4","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"6 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the original version of this article, the given and family names of Morvarid Ghamgosar Shahkhali were incorrectly structured. The name was displayed correctly in all versions at the time of publication. The original article has been corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Z.G-O. received consultancy fees from Lysosomal Therapeutics Inc. (LTI), Idorsia, Prevail Therapeutics, Ono Therapeutics, Denali, Handl Therapeutics, Neuron23, Bial Biotech, Bial, UCB, Capsida, Vanqua bio, Congruence Therapeutics, Takeda, Jazz Guidepoint, Lighthouse and Deerfield. Z.G-O. is affiliated with npj Parkinson\u2019s Disease as Associate Editor. A.J.N. reports grants from Parkinson\u2019s UK, Barts Charity, Cure Parkinson\u2019s, National Institute for Health and Care Research, Innovate UK, the Medical College of Saint Bartholomew\u2019s Hospital Trust, Alchemab, Aligning Science Across Parkinson\u2019s Global Parkinson\u2019s Genetics Program (ASAP-GP2) and the Michael J Fox Foundation. A.J.N. reports fees from AstraZeneca, AbbVie, Bial, and Britannia. K.S. reports grant from Parkinson Canada, Aligning Science Across Parkinson\u2019s Global Parkinson\u2019s Genetics Program (ASAP-GP2) and is a consultant for Acurex. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"352"}}